tiprankstipranks
Vertex Pharmaceuticals Inc. (DE:VX1)
NASDAQ:VX1
Germany Market
VX1
Vertex Pharmaceuticals
RESEARCH TOOLSreports

Vertex Pharmaceuticals (VX1) Stock Forecast & Price Target

22 Followers
See the Price Targets and Ratings of:

VX1 Analyst Ratings

Strong Buy
26Ratings
Strong Buy
21 Buy
4 Hold
1 Sell
Based on 26 analysts giving stock ratings to
Vertex
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VX1 Stock 12 Month Forecast

Average Price Target

€489.96
▲(16.44% Upside)
Based on 26 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is €489.96 with a high forecast of €582.42 and a low forecast of €303.34. The average price target represents a 16.44% change from the last price of €420.80.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"302":"€302","583":"€583","372.25":"€372.3","442.5":"€442.5","512.75":"€512.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":582.42178176,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€582.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":489.9607480890909,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€489.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":303.344678,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€303.34</span>\n  </div></div>","useHTML":true}}],"tickPositions":[302,372.25,442.5,512.75,583],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,411.1,424.2785985969231,437.4571971938462,450.63579579076924,463.81439438769235,476.9929929846154,490.1715915815385,503.35019017846156,516.5287887753847,529.7073873723077,542.8859859692308,556.0645845661538,569.243183163077,{"y":582.42178176,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,411.1,417.16621139146855,423.2324227829371,429.2986341744056,435.36484556587413,441.43105695734266,447.4972683488112,453.5634797402797,459.62969113174825,465.6959025232168,471.7621139146853,477.82832530615383,483.89453669762236,{"y":489.9607480890909,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,411.1,402.8111290769231,394.52225815384617,386.23338723076927,377.9445163076923,369.6556453846154,361.36677446153845,353.07790353846156,344.7890326153846,336.5001616923077,328.21129076923074,319.92241984615384,311.6335489230769,{"y":303.344678,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":396.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":346.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":366.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":368.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":391.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":398,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":415,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":389.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":366,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":373.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":439.45,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":411.1,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€582.42Average Price Target€489.96Lowest Price Target€303.34
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on DE:VX1
Brian Abrahams
RBC Capital
RBC Capital
€494.02
Buy
17.40%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Brookdale Senior Living (NYSE: BKD) and Legend Biotech (NASDAQ: LEGN)
Jefferies Analyst forecast on DE:VX1
Akash Tewari
Jefferies
Jefferies
€528.69→€548.62
Buy
30.38%
Upside
Reiterated
08/11/26
Jefferies Remains a Buy on Vertex Pharmaceuticals (VRTX)
Truist Financial Analyst forecast on DE:VX1
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/11/26
Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (NASDAQ: GEHC), Vertex Pharmaceuticals (NASDAQ: VRTX) and Agios Pharma (NASDAQ: AGIO)
Scotiabank Analyst forecast on DE:VX1
Louise Chen
Scotiabank
Scotiabank
€483.62
Buy
14.93%
Upside
Reiterated
08/11/26
Scotiabank Remains a Buy on Vertex Pharmaceuticals (VRTX)
Bernstein Analyst forecast on DE:VX1
William Pickering
Bernstein
Bernstein
€526.95
Buy
25.23%
Upside
Reiterated
08/11/26
Bernstein Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
William Blair Analyst forecast on DE:VX1
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
BMO Capital Analyst forecast on DE:VX1
Evan Seigerman
BMO Capital
BMO Capital
€520.02
Buy
23.58%
Upside
Reiterated
08/10/26
Vertex: Competitive Threat Eases, Pipeline Strength Supports Unchanged $600 Price Target and Buy Rating
Bank of America Securities Analyst forecast on DE:VX1
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€524.35→€582.42
Buy
38.41%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Jade Biosciences (NASDAQ: JBIO), Silence Therapeutics (NASDAQ: SLN) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Stifel Nicolaus Analyst forecast on DE:VX1
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€57.2→€433.35
Hold
2.98%
Upside
Reiterated
08/09/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Barclays Analyst forecast on DE:VX1
Eliana Merle
Barclays
Barclays
€533.02→€534.75
Buy
27.08%
Upside
Reiterated
08/05/26
Barclays Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
Maxim Group Analyst forecast on DE:VX1
Naz Rahman
Maxim Group
Maxim Group
€498.35
Buy
18.43%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Q32 Bio (NASDAQ: QTTB)
H.C. Wainwright Analyst forecast on DE:VX1
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€555.55
Buy
32.02%
Upside
Reiterated
08/04/26
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Stoke Therapeutics (STOK)
Evercore ISI Analyst forecast on DE:VX1
Cory Kasimov
Evercore ISI
Evercore ISI
€463.68
Buy
10.19%
Upside
Reiterated
08/04/26
Evercore ISI Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Needham Analyst forecast on DE:VX1
Joseph Stringer
Needham
Needham
―
Hold
―
Reiterated
08/04/26
Vertex Pharmaceuticals: Solid Q2 Beat and Raised 2026 Guidance, But Early-Stage Diversification and CRNX Integration Keep Rating at Hold
Canaccord Genuity Analyst forecast on DE:VX1
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€377.88→€383.08
Hold
-8.96%
Downside
Reiterated
08/04/26
Vertex: Solid CF Fundamentals and Early Pipeline Credit Drive Price Target Raise to $442, Hold Rating Maintained
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on DE:VX1
Brian Abrahams
RBC Capital
RBC Capital
€494.02
Buy
17.40%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Brookdale Senior Living (NYSE: BKD) and Legend Biotech (NASDAQ: LEGN)
Jefferies Analyst forecast on DE:VX1
Akash Tewari
Jefferies
Jefferies
€528.69→€548.62
Buy
30.38%
Upside
Reiterated
08/11/26
Jefferies Remains a Buy on Vertex Pharmaceuticals (VRTX)
Truist Financial Analyst forecast on DE:VX1
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/11/26
Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (NASDAQ: GEHC), Vertex Pharmaceuticals (NASDAQ: VRTX) and Agios Pharma (NASDAQ: AGIO)
Scotiabank Analyst forecast on DE:VX1
Louise Chen
Scotiabank
Scotiabank
€483.62
Buy
14.93%
Upside
Reiterated
08/11/26
Scotiabank Remains a Buy on Vertex Pharmaceuticals (VRTX)
Bernstein Analyst forecast on DE:VX1
William Pickering
Bernstein
Bernstein
€526.95
Buy
25.23%
Upside
Reiterated
08/11/26
Bernstein Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
William Blair Analyst forecast on DE:VX1
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
BMO Capital Analyst forecast on DE:VX1
Evan Seigerman
BMO Capital
BMO Capital
€520.02
Buy
23.58%
Upside
Reiterated
08/10/26
Vertex: Competitive Threat Eases, Pipeline Strength Supports Unchanged $600 Price Target and Buy Rating
Bank of America Securities Analyst forecast on DE:VX1
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€524.35→€582.42
Buy
38.41%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Jade Biosciences (NASDAQ: JBIO), Silence Therapeutics (NASDAQ: SLN) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Stifel Nicolaus Analyst forecast on DE:VX1
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€57.2→€433.35
Hold
2.98%
Upside
Reiterated
08/09/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Barclays Analyst forecast on DE:VX1
Eliana Merle
Barclays
Barclays
€533.02→€534.75
Buy
27.08%
Upside
Reiterated
08/05/26
Barclays Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
Maxim Group Analyst forecast on DE:VX1
Naz Rahman
Maxim Group
Maxim Group
€498.35
Buy
18.43%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Q32 Bio (NASDAQ: QTTB)
H.C. Wainwright Analyst forecast on DE:VX1
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€555.55
Buy
32.02%
Upside
Reiterated
08/04/26
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Stoke Therapeutics (STOK)
Evercore ISI Analyst forecast on DE:VX1
Cory Kasimov
Evercore ISI
Evercore ISI
€463.68
Buy
10.19%
Upside
Reiterated
08/04/26
Evercore ISI Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Needham Analyst forecast on DE:VX1
Joseph Stringer
Needham
Needham
―
Hold
―
Reiterated
08/04/26
Vertex Pharmaceuticals: Solid Q2 Beat and Raised 2026 Guidance, But Early-Stage Diversification and CRNX Integration Keep Rating at Hold
Canaccord Genuity Analyst forecast on DE:VX1
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€377.88→€383.08
Hold
-8.96%
Downside
Reiterated
08/04/26
Vertex: Solid CF Fundamentals and Early Pipeline Credit Drive Price Target Raise to $442, Hold Rating Maintained
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
ACRVAcrivon Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

3 Months
Mohit BansalWells Fargo
Success Rate
25/34 ratings generated profit
74%
Average Return
+7.87%
Copying Mohit Bansal's trades and holding each position for 3 Months would result in 73.53% of your transactions generating a profit, with an average return of +7.87% per trade.
1 Year
Salveen RichterGoldman Sachs
Success Rate
18/23 ratings generated profit
78%
Average Return
+13.08%
Copying Salveen Richter's trades and holding each position for 1 Year would result in 78.26% of your transactions generating a profit, with an average return of +13.08% per trade.
2 Years
Geoff MeachamCiti
Success Rate
40/41 ratings generated profit
98%
Average Return
+22.30%
Copying Geoff Meacham's trades and holding each position for 2 Years would result in 97.56% of your transactions generating a profit, with an average return of +22.30% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VX1 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
45
42
33
50
57
Hold
13
11
9
9
9
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
58
53
42
60
67
In the current month, VX1 has received 57 Buy Ratings, 9 Hold Ratings, and 1 Sell Ratings. VX1 average Analyst price target in the past 3 months is 489.96.
Each month's total comprises the sum of three months' worth of ratings.

VX1 Financial Forecast

VX1 Earnings Forecast

Next quarter’s earnings estimate for VX1 is €4.16 with a range of €3.19 to €4.49. The previous quarter’s EPS was €4.10. VX1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for VX1 is €4.16 with a range of €3.19 to €4.49. The previous quarter’s EPS was €4.10. VX1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.

VX1 Sales Forecast

Next quarter’s sales forecast for VX1 is €2.96B with a range of €2.89B to €3.04B. The previous quarter’s sales results were €2.90B. VX1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.
Next quarter’s sales forecast for VX1 is €2.96B with a range of €2.89B to €3.04B. The previous quarter’s sales results were €2.90B. VX1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.

VX1 Stock Forecast FAQ

What is DE:VX1’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals Inc.’s 12-month average price target is 489.96.
    What is DE:VX1’s upside potential, based on the analysts’ average price target?
    Vertex Pharmaceuticals Inc. has 16.44% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Vertex Pharmaceuticals Inc. a Buy, Sell or Hold?
          Vertex Pharmaceuticals Inc. has a consensus rating of Strong Buy, which is based on 21 buy ratings, 4 hold ratings and 1 sell ratings.
            What is Vertex Pharmaceuticals Inc.’s share price target?
            The average share price target for Vertex Pharmaceuticals Inc. is 489.96. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €582.42 ,and the lowest forecast is €303.34. The average share price target represents 16.44% Increase from the current price of €420.8.
              What do analysts say about Vertex Pharmaceuticals Inc.?
              Vertex Pharmaceuticals Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 26 Wall Streets Analysts.
                How can I buy shares of Vertex Pharmaceuticals Inc.?
                To buy shares of DE:VX1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.